Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
BNT162b2 anti-SARS-CoV-2 vaccine
VOCs
cancer
neutralizing antibody
third dose
Journal
ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
29
01
2022
revised:
28
02
2022
accepted:
03
03
2022
pubmed:
16
4
2022
medline:
4
5
2022
entrez:
15
4
2022
Statut:
ppublish
Résumé
Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 messenger RNA vaccine in cancer patients undergoing active treatment. Patients with solid cancer, vaccinated with a booster dose during active treatment, were enrolled in this study. Patients were classified into SARS-CoV-2 naïve (without previous COVID-19 infection) and SARS-CoV-2 experienced (with previous COVID-19 infection). Neutralizing antibody (NT Ab) titer and total anti-Spike immunoglobulin G (IgG) concentration were quantified in serum. Heparinized whole blood samples were used for SARS-CoV-2 Interferon Gamma Release Assay (IGRA). The primary endpoint was to assess the increase of IgG antibody level between baseline and 3 weeks after the booster. One hundred and forty-two consecutive patients were recruited. In SARS-CoV-2-naïve subjects, the median level of IgG was 157 BAU/ml [interquartile range (IQR) 62-423 BAU/ml] at T0 and reached a median of 2080 BAU/ml (IQR 2080-2080 BAU/ml) at 3 weeks after booster administration (T1; P < 0.0001). A median 16-fold increase of SARS-CoV-2 NT Ab titer (IQR 4-32) was observed in naïve subjects (from median 20, IQR 10-40, to median 640, IQR 160-640; P < 0.0001). Median interferon-γ level at T1 was significantly higher than that measured at T0 in SARS-CoV-2-naïve subjects (P = 0.0049) but not in SARS-CoV-2-experienced patients. The median level of SARS-CoV-2 NT Abs was 32-fold lower against Omicron compared to the wild-type strain (P = 0.0004) and 12-fold lower compared to the Delta strain (P = 0.0110). The third dose is able to trigger both the humoral and the cell-mediated immune response in cancer patients on active treatment. Our preliminary data about the neutralization of the SARS-CoV-2 vaccine against variants of concern seem to confirm the lower vaccine activity.
Sections du résumé
BACKGROUND
Although a full course of coronavirus disease 2019 (COVID-19) vaccine is effective in cancer patients, the duration of the protection and the efficacy of a booster dose against the new variants remain unknown. We prospectively evaluated the immunogenicity of the third dose of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 messenger RNA vaccine in cancer patients undergoing active treatment.
PATIENTS AND METHODS
Patients with solid cancer, vaccinated with a booster dose during active treatment, were enrolled in this study. Patients were classified into SARS-CoV-2 naïve (without previous COVID-19 infection) and SARS-CoV-2 experienced (with previous COVID-19 infection). Neutralizing antibody (NT Ab) titer and total anti-Spike immunoglobulin G (IgG) concentration were quantified in serum. Heparinized whole blood samples were used for SARS-CoV-2 Interferon Gamma Release Assay (IGRA). The primary endpoint was to assess the increase of IgG antibody level between baseline and 3 weeks after the booster.
RESULTS
One hundred and forty-two consecutive patients were recruited. In SARS-CoV-2-naïve subjects, the median level of IgG was 157 BAU/ml [interquartile range (IQR) 62-423 BAU/ml] at T0 and reached a median of 2080 BAU/ml (IQR 2080-2080 BAU/ml) at 3 weeks after booster administration (T1; P < 0.0001). A median 16-fold increase of SARS-CoV-2 NT Ab titer (IQR 4-32) was observed in naïve subjects (from median 20, IQR 10-40, to median 640, IQR 160-640; P < 0.0001). Median interferon-γ level at T1 was significantly higher than that measured at T0 in SARS-CoV-2-naïve subjects (P = 0.0049) but not in SARS-CoV-2-experienced patients. The median level of SARS-CoV-2 NT Abs was 32-fold lower against Omicron compared to the wild-type strain (P = 0.0004) and 12-fold lower compared to the Delta strain (P = 0.0110).
CONCLUSIONS
The third dose is able to trigger both the humoral and the cell-mediated immune response in cancer patients on active treatment. Our preliminary data about the neutralization of the SARS-CoV-2 vaccine against variants of concern seem to confirm the lower vaccine activity.
Identifiants
pubmed: 35427842
pii: S2059-7029(22)00075-8
doi: 10.1016/j.esmoop.2022.100458
pmc: PMC8913298
pii:
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Immunoglobulin G
0
Vaccines, Synthetic
0
mRNA Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100458Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure The authors have declared no conflicts of interest.
Références
J Neurooncol. 2022 Feb;156(3):483-489
pubmed: 35018613
ESMO Open. 2021 Oct;6(5):100272
pubmed: 34543863
Clin Cancer Res. 2021 Dec 15;27(24):6815-6823
pubmed: 34583970
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
N Engl J Med. 2021 Nov 4;385(19):1761-1773
pubmed: 34525277
JAMA Oncol. 2022 Feb 1;8(2):300-301
pubmed: 34812840
Cancer Cell. 2022 Jan 10;40(1):3-5
pubmed: 34838186
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34
pubmed: 30930717
N Engl J Med. 2021 Dec 23;385(26):2413-2420
pubmed: 34879190
ESMO Open. 2022 Feb;7(1):100359
pubmed: 34973510
Cancer Cell. 2022 Feb 14;40(2):117-119
pubmed: 34986328
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Sci Adv. 2021 Sep 03;7(36):eabj5365
pubmed: 34516917
J Infect Dis. 2022 May 11;:
pubmed: 35543278
Am J Transplant. 2022 Apr;22(4):1253-1260
pubmed: 34951746
Eur J Cancer. 2022 Jan;160:243-260
pubmed: 34794855
Euro Surveill. 2020 Jun;25(24):
pubmed: 32583766
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Eur J Cancer. 2022 Mar;163:177-179
pubmed: 35077960
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Cell. 2022 Feb 3;185(3):457-466.e4
pubmed: 34995482
Eur J Cancer. 2022 Apr;165:184-194
pubmed: 35248840